TScan Therapeutics, Inc. - stock earnings
TCRX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -19.6 million USD | 7.2 million USD |
| 2023Q3 | -23.0 million USD | 3.9 million USD |
| 2023Q2 | -24.0 million USD | 3.1 million USD |
| 2023Q1 | -23.3 million USD | 6.8 million USD |
| 2022Q4 | -18.8 million USD | 1000 USD |
| 2022Q3 | -15.9 million USD | 3.4 million USD |
| 2022Q2 | -14.9 million USD | 4.1 million USD |
| 2022Q1 | -16.1 million USD | 3.0 million USD |
| 2021Q4 | -14.2 million USD | 2.9 million USD |
| 2021Q3 | -15.8 million USD | 2.4 million USD |
| 2021Q2 | -10.7 million USD | 2.8 million USD |
| 2021Q1 | -7.9 million USD | 2.0 million USD |
| 2020Q4 | -7.8 million USD | 795000 USD |
| 2020Q3 | -7.2 million USD | 290000 USD |
| 2020Q2 | -5.6 million USD | ? USD |
| 2020Q1 | -5.5 million USD | 57.6 million USD |
TCRX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -89.2 million USD | 21.0 million USD |
| 2022 | -65.8 million USD | 13.5 million USD |
| 2021 | -48.6 million USD | 10.1 million USD |
| 2020 | -26.0 million USD | 1.1 million USD |
| 2019 | -13.1 million USD | ? USD |
TCRX
Price: $8.56
52 week price:
Earnings Per Share: -1.36 USD
P/E Ratio: -2.59
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 133500
Market Capitalization: 371.3 million
Average Dividend Frequency: 4